About: Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.05 (+3.54%)
ERNA NASDAQ Eterna Therapeutics Inc
Eterna Therapeutics Inc share price
Atividade de preço de ERNA
Último preço
$ 2,050
Variação (24h)
0,07 USD (3,54%)
Volume
3.22K
Volume (média 4 sem.)
-
Abertura
$ 2,03
Variação do dia
$ 2,01 - $ 2,05
Fechamento anterior
$ 1,98
Último negócio
29 Oct, 3:36 pm GMT+0
Atrasado
29 Oct, 3:36 pm GMT+0
ERNA price performance
Atrasado
29 Oct, 3:36 pm GMT+0
quote.marketSignals